Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype

Pharmacogenetics

Volumn 9, Issue 6, 1999, Pages 707-714

  Wennerholm, Agneta ^a   Johansson, Inger ^c   Massele, Amos Y ^b   Jande, Mary ^b   Alm, Christina ^a   Aden Abdi, Yakoub ^a   Dahl, Marja Liisa ^a   Ingelman Sundberg, Magnus ^c   Bertilsson, Leif ^a   Gustafsson, Lars L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MUHIMBILI MEDICAL CENTRE   (Tanzania)

^c NONE

Author keywords

Bantu; CYP2D locus; Extensive metabolizers; Genetic polymorphism

Indexed keywords

4 HYDROXYDEBRISOQUINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; MEPHENYTOIN;

ADULT; ARTICLE; DRUG METABOLISM; DRUG URINE LEVEL; ETHIOPIA; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC CAPACITY; NEGRO; NORMAL HUMAN; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; TANZANIA; ZIMBABWE;

EID: 0033429268     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199912000-00005     Document Type: Article

References (43)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gaultier J-C, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44:707-715.
2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-146.
3. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-537.
4. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-397.
5. Bertilsson L, Dahl M-L, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational mega-prescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63.
6. Bertilsson L, Dahl M-L, Ingelman-Sundberg M, Johansson I, Sjöqvist F. Interindividual and interethnic differences in polymorphic drug oxidation-Implication for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Luxemburg: Office for Official Publications of the European Communities. DGXII-E-4 EUR 1 54 39 EN, EC; 1995. pp. 85-136.
7. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. 1st edn. Princetown University Press; 1994. pp. 165-171.
8. Chang KC, Lauer BA, Bell TD, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 1:1132-1133.
9. Dahl M-L, Johansson I, Porsmyr-Palmertz M, Ingelman-Sundberg M. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51:12-17.
10. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-520.
11. Dalén P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63:444-452.
12. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
13. De Sommers K, Moncrieff J, Avenant J. Non-correlations betwen debrisoquine and metoprolol polymorphism in the Venda. Human Toxicol 1989; 8:365-368.
14. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8:325-333.
15. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
16. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998; 64:391-401.
17. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Disp 1985; 13:443-448.
18. Ingelman-Sundberg M. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics. Proceedings of the 1996 EUROTOX Congress Meeting; Applied toxicology: approaches through basic science; 1997.
19. Iyun AO, Lennard MS, Tucker GT, Woods HF. Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40:387-394.
20. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci 1993; 90:11825-11829.
21. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46:452-459.
22. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6:351-355.
23. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of a polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-905.
24. Leathart JBS, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8:529-541.
25. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxymetabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977; 133:161-168.
26. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
27. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999; 226:327-338.
28. Marez U, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
29. Masimirembwa CM, Hasler JA. Genetic polymorphism of drug metabolising enzymes in African populations - implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997; 44:561-571.
30. Masimirembwa CM, Johansson I, Hasler UA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3:275-280.
31. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996a; 42:713-719.
32. Masimirembwa C, Hasler J, Bertilsson L, Johansson I, Ekberg O, Ingelman-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996b; 51:117-122.
33. Masimirembwa CM, Gustafsson LL, Dahl M-L, Abdi YA, Hasler JA. Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br J Clin Pharmacol 1996c; 41:344-346.
34. Mbafeno C, Bababunmi EA, Mahqoub A, Sloan TP, Idle JR, Smith RL. A study of debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980; 10:811-818.
35. O'Neil WM, Di Girolamo A, Gilfix BM, Flockhart DA, Tsoukas CM, Wainer IW. The genotype and expressed phenotype of cytochrome P450 2D6 among HIV+/AIDS patients [abstract]. Clin Pharmacol Ther 1998; 63:151.
36. Roh H-K, Dahl M-L, Johansson I, Ingelman-Sundberg M, Cha Y-N, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6:441-447.
37. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
38. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45:495-499.
39. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994; 3:923-926.
40. Simooya OO, Sijumbil G, Lennard MS, Tucker GT. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 1998; 45:315-317.
41. Standard treatment guidelines and the national essential drugs list for Tanzania (NEDLIT). Tanzania: Ministry of Health, United Republic of Tanzania World Health Organization: 1991.
42. Wang S-L, Huang J-D, Lai M-D, Liu B-H, Lai M-L. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53:410-418.
43. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquine/ phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37:512-521.